Literature DB >> 27548061

Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.

Michal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov R Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0155711.].

Entities:  

Year:  2016        PMID: 27548061      PMCID: PMC4993487          DOI: 10.1371/journal.pone.0161799

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


The fourteenth author’s name is spelled incorrectly. The correct name is: Yaacov R. Lawrence Additionally, there are errors in the author affiliations. The affiliations should appear as shown here: Michal Yalon1,2, Liron Tuval-Kochen2,3, David Castel3,4, Itai Moshe1, Inbal Mazal2, Osher Cohen5, Camila Avivi6, Kineret Rosenblatt6, Sarit Aviel-Ronen6, Ginette Schiby6, Joachim Yahalom7, Ninette Amariglio2,8, Raphael Pfeffer2, Yaacov R. Lawrence2,3, Amos Toren1,2, Gideon Rechavi2,3, Shoshana Paglin2 1 Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Sheba Medical Center Ramat-Gan 52621, Israel 2 Cancer Research Center, Sheba Medical Center, Ramat-Gan 52621, Israel 3 Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 4 Neufeld Cardiac Research Institute, Sheba Medical Center, Ramat-Gan 52621, Israel 5 Department of Surgery, Sheba Medical Center, Ramat-Gan 52621, Israel 6 Department of Pathology, Sheba Medical Center, Ramat-Gan 52621, Israel 7 Department of Radiation Oncology, Memorial Sloan Kettering, NYC 10021, USA 8 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 52900, Israel Finally, there are errors in the funding section. The complete, correct Funding Statement is: http://ec.europa.eu/research/mariecurieactions/ Grant # PCIG10-GA-2011-303795 (Y.L.), Chaya and Kadish Shermeister endowment (The Laboratory of Experimental Radiotherapy), the estate of Miss HARAN ESTER of blessed memory through Keren Izvonot, Israel Ministry of Health (S.P.) and the Bencuya Family Foundation (L.T.K., R.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
  1 in total

1.  Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.

Authors:  Michal Yalon; Liron Tuval-Kochen; David Castel; Itai Moshe; Inbal Mazal; Osher Cohen; Camila Avivi; Kineret Rosenblatt; Sarit Aviel-Ronen; Ginette Schiby; Joachim Yahalom; Ninette Amariglio; Raphael Pfeffer; Yaacov Lawrence; Amos Toren; Gideon Rechavi; Shoshana Paglin
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  1 in total
  2 in total

1.  Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.

Authors:  Gamze Guney Eskiler; Gulsah Cecener; Unal Egeli; Berrin Tunca
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

2.  BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.

Authors:  Paul Mayor; Laurie M Gay; Shashikant Lele; Julia A Elvin
Journal:  Gynecol Oncol Rep       Date:  2017-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.